An interventional study of middle meningeal artery embolization in Middle Meningeal Artery Embolization and Chronic Subdural Hematomas, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Primary : to evaluate the efficacy of MMAE on resolution and recurrence of hematoma in patients with CSDH.
Secondary : evaluate the effect of MMAE on functional outcome, radiological changes, the need to repeat surgery, duration of hospital stay, time for hematoma to resolve.
Chronic subdural hematoma(CSDH) is one of the most common neurosurgical disorders, particularly among older adults, and its incidence continues to increase worldwide because of population aging and the growing use of anticoagulant and antiplatelet medications. The condition usually develops following minor head trauma that results in rupture of bridging veins; however, current evidence suggests that the persistence and enlargement of CSDH are primarily driven by chronic inflammation, angiogenesis, and recurrent microhemorrhages originating from fragile neovascular membranes rather than the initial bleeding event alone. These pathological mechanisms contribute to progressive hematoma expansion, neurological deterioration, and substantial morbidity and mortality if left untreated.Surgical evacuation through burr-hole remains the standard treatment for symptomatic CSDH and is generally associated with rapid neurological improvement. Nevertheless, postoperative recurrence remains a major challenge, with recurrence rates ranging from approximately 8% to 20%, often necessitating repeat surgical intervention. Recurrent hematomas increase healthcare costs, prolong hospitalization, and are associated with poorer functional recovery, particularly in elderly and medically frail patients. Consequently, there has been increasing interest in adjunctive therapies that target the underlying pathophysiology responsible for recurrence rather than simply evacuating the hematoma.Middle meningeal artery embolization (MMAE) has recently emerged as a promising minimally invasive treatment for CSDH. The rationale for MMAE is based on occluding the vascular supply to the outer neomembrane of the hematoma, thereby reducing ongoing inflammatory exudation and recurrent microhemorrhage that sustain hematoma growth. Unlike conventional surgery, which addresses the hematoma itself, embolization targets the biological process responsible for hematoma persistence and recurrence. As a result, MMAE has been investigated both as a standalone therapy for selected patients and as an adjunct to surgical evacuation to reduce postoperative recurrence.MMAE significantly reduces the risk of hematoma recurrence and the need for repeat surgery compared with standard treatment alone, without increasing serious complications or mortality. However, although recurrence outcomes have shown clear improvement, the effect of MMAE on functional recovery, commonly assessed using the Glasgow Coma Scale (GCS).
112 studies on the registry are indexed under Hematoma, Subdural, Chronic; 49 are open to participants now.
This study's planned enrollment of 35 is below the median of 185 across 86 interventional studies indexed under Hematoma, Subdural, Chronic.
Browse Hematoma, Subdural, Chronic studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subdural hematomas secondary to:
to angiography or embolization (for the MMAE group), such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: middle meningeal artery embolization
Middle meningeal artery (MMA) embolization is a minimally invasive endovascular procedure designed to treat chronic subdural hematomas by blocking blood flow to the MMA, preventing recurrent bleeding. Under local or general anesthesia, a catheter is inserted through a micro-puncture in the femoral or radial artery and navigated up to the external carotid system into the MMA under real-time fluoroscopic (X-ray) guidance. Angiography is performed to map the arterial anatomy and identify any dangerous anastomoses with the ophthalmic or internal carotid arteries. Once positioned safely, an embolic agent such as liquid embolic systems (e.g., Onyx, n-BCA), liquid-suspended microparticles (PVA), or microcoils is injected into the anterior and posterior branches of the MMA. This occludes the fragile, hypervascular membranes driving the hematoma, allowing the body to naturally reabsorb the collected blood and reducing the need for open surgical evacuation.
Recurrence Requiring Additional Surgical Intervention
Composite outcome defined as recurrence of chronic subdural hematoma requiring repeat surgical intervention within 6 months. Recurrence may be identified by radiological enlargement or reaccumulation of the hematoma on CT associated with recurrent or worsening neurological symptoms leading to reoperation.
Time frame: six months
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.
Of 44 interventional studies with no phase under Hematoma, Subdural, Chronic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.